CNS Delivery of Immunotherapy Using MSCs

Principal Investigator

Regents of the Univ. of California
Irvine, CA
Acknowledgement
This project was funded by the Revocable Trust of Margery de Scheweinitz, deceased. ADR 2006

Detailed Non-Technical Summary

The focus of this proposal is on immunotherapy (vaccine) as an experimental approach to treat Alzheimer's disease. Dr. Cribbs plans to directly delivery specific antibodies to the central nervous system to attack the toxic amyloid peptide that accumulates in the brain. The antibodies will be delivered by the patient's own stem cells which will be isolated from their bone marrow. These stem cells will be genetically modified to make the antibodies, and then they will be injected into the brain where they will go to the sites of brain inflammation and secrete the therapeutic antibodies.

First published on: June 11, 2008

Last modified on: February 03, 2023